Trenimon Treatment in Chronic Hemoblastoses

Abstract

Summary 1. Trenimon has three remarkable pharmacological characteristics, namely: very low toxicity, easy way of employing, big therapeutic action. 2. It results particularly useful in lymphatic and myeloid chronic leukemias, Vaquez's disease, hemorrhagic thrombocythemia, Waldenstrom's disease. It has to be noticed that Trenimon action is valuable in chronic myeloid leukemia even when it has been already treated with Busulphan for a long time. 3. Good results are obtained also in several cases of Hodgkin's disease, while the drug is less efficacious in Lympho-reticulosarcoma. Uncertain still being its action in plasmacytoma.